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Improved tumor contrast achieved by single time point
dual-reporter fluorescence imaging
Kenneth M. Tichauer,a Kimberley S. Samkoe,a,b Kristian J. Sexton,a Jason R. Gunn,a Tayyaba Hasan,c and
Brian W. Poguea,b,c
aDartmouth College, Thayer School of Engineering, Hanover, New Hampshire 03755
bDartmouth Medical School, Department of Surgery, Lebanon, New Hampshire 03756
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Abstract. In this study, we demonstrate a method to quantify biomarker expression that uses an exogenous dual-
reporter imaging approach to improve tumor signal detection. The uptake of two fluorophores, one nonspecific and
one targeted to the epidermal growth factor receptor (EGFR), were imaged at 1 h in three types of xenograft tumors
spanning a range of EGFR expression levels (n ¼ 6 in each group). Using this dual-reporter imaging methodology,
tumor contrast-to-noise ratio was amplified by >6 times at 1 h postinjection and >2 times at 24 h. Furthermore, by
as early as 20 min postinjection, the dual-reporter imaging signal in the tumor correlated significantly with a
validated marker of receptor density (P < 0.05, r ¼ 0.93). Dual-reporter imaging can improve sensitivity and
specificity over conventional fluorescence imaging in applications such as fluorescence-guided surgery and
directly approximates the receptor status of the tumor, a measure that could be used to inform choices of biological
therapies. © 2012 Society of Photo-Optical Instrumentation Engineers (SPIE). [DOI: 10.1117/1.JBO.17.6.066001]
Keywords: binding potential; epidermal growth factor receptor; fluorescence; receptor; xenograft; molecular imaging; cancer.
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1 Introduction
Targeted fluorescent imaging reporters are being used to an
ever-greater extent in surgical oncology as a means of improving
tumor contrast to guide resection or highlight sensitive tissues
that should be avoided.1,2 The promise of fluorescence-guided
surgery to reduce morbidity and mortality has stimulated a num-
ber of clinical studies and clinical trials focused on the surgical
treatment of oncological pathologies.3–9 To date, the vast major-
ity of these applications have employed clinically approved
fluorescent reporters, which has somewhat limited the number
of pathologies to which fluorescence-guided surgery has been
applied. However, there is a large and growing number of tar-
geted fluorescent agents that have been employed and presented
in preclinical studies,10 and as the field matures, more and more
of these targeted reporters will become clinically available. As
they do become available, it will be important to determine
optimal procedures for imaging their uptake.
The most obvious approach to imaging targeted fluorescence
uptake in tumors is to inject the reporter systemically and then
wait several hours or days before imaging. The exact delay time
between injection and imaging is ideally chosen to allow non-
specific tissue uptake of the fluorescent reporter to wash away,
as well as to allow the reporter to be filtered out of the blood-
stream, providing better contrast for reporter that is presumably
bound to disease-specific receptors in cancerous lesions. At later
times, however, uptake is typically governed more by the
enhanced permeability and retention effect11 or cellular interna-
lization12 of the reporter, and therefore this approach may not
exploit the full potential of the targeted binding. In fact, at
these late time points, even untargeted reporters such as indo-
cyanine green are preferentially taken up by tumors.7 There are
further delivery limitations of this approach as well. First, the
uptake of a fluorescent reporter, even at 24 h, is still dependent
on the rate of delivery of the reporter, so it is not obvious how
well it will work for more avascular tumors.13 Second, achieving
sufficient signal in the tumor at these delayed time points may
require larger doses of the reporter than necessary, which could
impede the clinical acceptance of these approaches. Ideally,
microdose levels (<30 nmol∕dose) of tracers can be used to
measure uptake, which would dramatically ease the require-
ments for U.S. Food and Drug Administration (FDA)
approval.14 Finally, recent developments in activatable fluores-
cent reporters, which fluoresce only upon binding with their
specific antigen, provide a means of compensating for some of
these complications;15,16 however, their uptake is still dependent
on vascular permeability-mediated delivery of the reporter, and
their ability to be preferentially retained at the site of activation
varies with reporter type.
As a means of accounting for some of these transport-
mediated aspects of targeted reporter uptake, a number of
groups have investigated the employment of an untargeted
reporter for referencing.17–19 Recent work demonstrated
that the simultaneous injection of an untargeted fluorescent
reporter along with a targeted reporter can be used to image
reporter—receptor binding in vivo20 and can further be used
to quantify receptor expression21 based on “reference tissue”
modeling practices.22,23 The benefits of this approach are that
any variations in reporter delivery, tissue hemodynamics,
blood volume, or nonspecific uptake within a tumor or between
tumor types are accounted for by measuring the uptake curve of
the untargeted reporter. This enables the approach to be carriedAddress all correspondence to: Kenneth M. Tichauer, Thayer School of Engineer-
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out immediately after reporter injection, when the amount of
fluorescence signal in the tissue is at a maximum, thereby
enabling the lowest concentrations of reporters to be adminis-
tered. The downside to the approaches demonstrated thus
far20,21 is that they require continuous monitoring of the uptake
curves of both reporters over tens of minutes, which would not
be ideal for translation to fluorescence-guided surgery.
In this study, a simplified version of this approach is pre-
sented with a focus on achieving optimal tumor-to-background
contrast at single time points by essentially taking the ratio of the
uptake images of the two reporters: one untargeted and, for
investigational purposes, one targeted to epidermal growth fac-
tor receptor (EGFR), a cell surface receptor that is overexpressed
in many forms of cancer.24 This single timeframe imaging of the
processed image was hypothesized to have enhanced contrast as
well as be closely related to the EGFR expression activity of
the tumor.
2 Materials and Methods
2.1 Dual-Reporter Model
Using a two-tissue compartment model to approximate the tis-
sue distribution of the targeted imaging reporter and a one-tissue
compartment model to approximate the tissue distribution of the
untargeted reporter (Fig. 1), it is possible to demonstrate that the
ratio of uptake of the two reporters at any given time point is
proportional to the receptor density of the tissue interest. Spe-
cifically, the concentration of the targeted imaging reporter in a
region of interest was modeled as a sum of the concentration of
the reporter in the blood and in two tissue compartments: the
blood plasma concentration, Cp; the unbound or nonspecifically
bound concentration in the interstitial space, Cf ; and the concen-
tration of reporter attached to its specific receptor, Cb. Addition-
ally, the concentration of the untargeted reporter was modeled as
a sum of the blood plasma concentration, Cp, and the unbound
or nonspecifically bound concentration in the interstitial space,
Cr. These relationships can be expressed by the following
equations if both reporters are assumed to have the same plasma
curves:
ROITðtÞ ¼ CpðtÞ þ Cf ðtÞ þ CbðtÞ and (1)
ROIUTðtÞ ¼ CpðtÞ þ CrðtÞ; (2)
where ROITðtÞ and ROIUTðtÞ are the measured region of interest
concentrations of the targeted and untargeted reporters, respec-
tively, as a function of time t. Taking the difference between
Eqs. (1) and (2) and then dividing by Eq. (2) (i.e., subtracting
the untargeted reporter uptake image from the targeted image




¼ Cf ðtÞ þ CbðtÞ − CrðtÞ
CpðtÞ þ CrðtÞ
: (3)
If it is assumed that Cf and Cr are roughly equivalent and






Depending on the tumor kinetic parameters, the assumption that
CP ≪ Cr may or may not be true25; however, by 30 min post-
injection, inclusion of a typical tracer plasma concentration
curve from an independent study26 assuming a 5% tumor
blood volume had a <1% effect on the ratio measured in
Eq. (4) in the current study (results not shown).
If first-order kinetics are assumed, then based on the com-
partment model present in Fig. 1, the following relationship
between Cf and Cb can be derived:
Fig. 1 An illustration of the theoretical relationship between the targeted and untargeted reporter uptake in a region of interest and the binding potential
(BP: a correlate of receptor density) is shown. The two-tissue compartment model is depicted in (a) and represents the distribution of the targeted
reporter in the blood, unbound in the tissue space, and specifically bound in the tissue space. The tracer is modeled to move between the compartments
governed by the rate constants K1, K2, K3, and K4. The one-tissue compartment model is depicted in (b) and represents the distribution of the untargeted
reporter in the blood and unbound in the tissue space (reference space). Assuming the plasma concentration is negligible and the unbound concen-
trations of the targeted and untargeted reporters are equivalent, it is possible to show that ratio on the left side of the expression is approximately
equivalent to the binding potential (BP), which is directly proportional to receptor availability.
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dCbðtÞ
dt
¼ k3Cf ðtÞ − k4CbðtÞ; (5)
where k3 is the rate constant governing the binding of reporter
in the interstitial space to specific receptors and k4 is the rate
constant governing the separation of the bound reporter from
its specific receptor back into the interstitial space. Finally, if
it is assumed that after a given initial time Cb and Cf are in
equilibrium (i.e., dCbðtÞ∕dt ¼ 0), then k3∕k4 can be substituted






where k3∕k4 is, by definition, the binding potential, BP, which is
equal to the product of the affinity of the targeted reporter for its
receptor and the receptor density.27 Because the ratio on the left-
hand side of Eq. (6) is proportional to the binding potential, it
follows that contrast in a dual-reporter image is driven by the
level of expression of the targeted receptor and not other factors
such as hemodynamic delivery of the reporter or the amount of
reporter injected.
2.2 Animal Experiments
To investigate the potential of the proposed dual-reporter ima-
ging approach for improving tumor discrimination, a study was
conducted on 32 immune-deficient SCID mice (Charles River,
Wilmington, MA). Twenty-six-week-old mice were inoculated
with a human neuronal glioblastoma (U251; supplied from
Dr. Mark Israel, Norris Cotton Cancer Center, Dartmouth-
Hitchcock Medical Center), a cancer cell line known to express
moderate levels of EGFR;28,29 another six mice were inoculated
with a human epidermoid carcinoma (A431; ATCC, Manassas,
VA), known to express a very large amount of EGFR;30 and the
final six mice were inoculated with a rat gliosarcoma (9L-GFP;
supplied by Dr. Bogdanov, Dartmouth Medical School), a cell
line known to express very little EGFR.28 In all cases, the tumors
were introduced by injecting 1 × 106 tumor cells in Matrigel®
(BD Biosciences, San Jose, CA) into the subcutaneous space on
the left thigh of the mice. The tumors were then allowed to grow
to a size of approximately 150 mm3 before imaging (roughly 2
weeks). For imaging, the mice were separated into two larger
groups. In the first group, which included nine U251 mice,
six 9L-GFP mice, and six A431 mice, the uptake of both an
untargeted fluorescence reporter (carboxylate form of the
IRDye 700DX NHS Ester; LI-COR Biosciences, Lincoln,
NE) and an EGFR-targeted fluorescence reporter (IRDye
800CW EGF; LI-COR Biosciences, Lincoln, NE) was imaged
at approximately 5-min intervals in the first hour after intrave-
nous injection. In the second group, which included the remain-
ing 11 U251 mice, the uptake of the two reporters was imaged at
a single time point 24 h after reporter injection. In the first
group, three of the U251 mice were injected with the fluorescent
reporter cocktail 15 min after a 30-nmol (100 mL PBS) intra-
venous injection of free human recombinant EGF (Millipore,
Temecula, CA) to carry out a blocking study (negative control).
This was repeated for five of the mice in the 24-h imaging pro-
tocol, and these mice are referred to as “U251 Block” in the
figures. To account for intensity differences due to quantum
yield and relative reporter concentrations, as well as imaging
efficiency differences at the two wavelength bands, for the
two reporters, the untargeted fluorescence images at all time
points were multiplied by the ratio of targeted to untargeted
fluorescence measured from the injected fluorescent cocktail
using the imaging system.
2.3 Imaging Protocol
Just before imaging, the mice were anesthetized with ketamine-
xylazine (100∶10 mg∕kg i.p.), and the superficial tissue sur-
rounding the tumors was removed. Each mouse was then placed
tumor side down on a glass slide and loosely secured with
surgical tape. Once plated, the mice were positioned onto the
imaging plane of an Odyssey Scanner (LI-COR Biosciences,
Lincoln, NE). The Odyssey Scanner employs raster scanning
and two lasers (emitting at 685 and 785 nm) to excite the
targeted and untargeted fluorophores simultaneously, pixel by
pixel, and uses a series of dichroic mirrors to decouple
fluorescence from the LI-COR 700-nm fluorescent reporter
and the LI-COR 800-nm fluorescent reporter.
2.4 Image Analysis
Amajor purpose of this study was to compare the tumor contrast
attainable with the dual-reporter approach to a conventional
fluorescence-guided surgery approach that achieves contrast
through targeted fluorescence uptake alone. To accomplish
this, contrast was quantified by calculating the average signal
in the tumor and subtracting the average signal in the
skin. Then this contrast value was divided by the standard devia-
tion (SD) of signal in the skin to estimate contrast-to-noise
ratio (CNR). This calculation can be displayed mathematically
as follows:
CNRðtÞ ¼ StuðtÞ − SskðtÞ
σskðtÞ
; (7)
where StuðtÞ is the average signal measured in the tumor, SskðtÞ
is the average signal in the skin, and σskðtÞ is the SD of the signal
in the skin at time t. Figure 2 demonstrates the utility of CNR
over the tumor-to-background ratio typically used to evaluated
fluorescence images. The figure depicts two simulated signal
profiles transecting two regions, a background region and a
tumor region (given positive contrast), from a theoretical
image. It is obvious from the figure that the location of the
tumor is considerably more apparent in the red profile than
the blue profile; however, both profiles exhibit the same
tumor-to-background ratio (tumor signal/background signal)
of 11. On the other hand, the CNR is 16.0 for the red profile
and 1.6 for the blue profile, showing that CNR better represents
the ability to visually discriminate contrast in an image.
A receiver operating characteristic (ROC) curve analysis was
also carried out to further investigate the strength of each ima-
ging approach for localizing a tumor. It was completed on an
image-by-image basis for both the targeted fluorescence images
and the dual-reporter images in all unblocked U251 mice at 1
and 24 h postinjection. The ROC was automated by setting the
upper threshold in each image to the maximum pixel value in the
image and adjusting the lower threshold incrementally by 5% of
the maximum value from zero up to the maximum pixel value.
At each increment, every pixel of the image was characterized as
follows: if it was part of the tumor, it was recorded as a true
positive (TP) if its value was greater than the lower threshold
and a false positive (FP) if its value was less than the lower
threshold. Conversely, if the pixel was not part of the tumor,
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it was recorded as a false negative (FN) if its value was greater
than the lower threshold and a true negative (TN) if its value was
less than the lower threshold. The location of the tumor
was determined from white-light images taken of the mouse
before imaging. Following this characterization, the standard
principles of ROC analysis were employed. Specifically, for
each image the sensitivity ¼ TP∕ðTPþ FNÞ and specificity ¼
TN∕ðFPþ TNÞ were calculated at each threshold and ROC
curves were created (sensitivity versus 1—specificity). Finally,
the area under the ROC curve was calculated for all images to
estimate the accuracy of the targeted fluorescence uptake and
dual-reporter approaches for correctly identifying tumor over
normal tissue.
2.5 Statistics
All statistical analyses were carried out with the statistical soft-
ware package, SPSS (IBM®, Armonk, NY). For temporal ana-
lyses, a mixed two-way repeated-measures ANOVAwith time as
the within-subject variable and tumor group as the between-
subject factor was employed. A two-way mixed ANOVA
with Bonferroni correction was used to analyze tumor
contrast-to-noise for each imaging method and at each imaging
time point after reporter injection. Linear regression was
employed to compare dual-reporter results with in vivo binding
potentials.21 Statistical significance was based on P < 0.05. All
data are presented as mean SD unless stated otherwise.
3 Results
Figrue 3 presents representative targeted and untargeted fluor-
escence images, as well as the corresponding white-light
image and a dual-reporter image, in each tumor group at 1 h
after intravenous injection of a mixture of EGFR-targeted
and untargeted fluorescent reporters (fluorescing at 800 and
700 nm, respectively). In a strictly qualitative sense, for the
two tumors that are known to express EGFR (A431 and
U251), it was easier to locate the tumor using the dual-reporter
image [from Eq. (6)] than with the targeted or untargeted fluor-
escence images alone at 1 h. Figure 4 elaborates on these obser-
vations, presenting a more quantitative analysis. In Fig. 4(a), the
average CNRs of targeted fluorescence uptake in A431, U251,
9L-GFP, and blocked U251 tumors are depicted within 1 h after
injection of the dual-reporter mixture. A repeated-measures
mixed ANOVA demonstrated a significant two-way effect in
the data in the form of a significant time-by-tumor line effect
(P < 0.01). This suggested that the dynamics of the tumor
lines were significantly different; in particular, the U251 tumors
tended to exhibit a quicker release of the targeted reporter after
injection than the other groups. Despite this effect, however, the
between-subject omnibus test suggested that uptake differences
were not significant between the tumor lines, at any time point in
any tumor line, and no correlation was found between targeted
fluorescence uptake and the expected magnitude of EGFR
expression in the different tumor lines at any time point. On
the other hand, the time courses of the dual-reporter tumor
CNRs [depicted in Fig. 3(b)] demonstrated a clear ability to
resolve the location of the tumor using dual-reporter imaging
Fig. 2 Two theoretical signal profiles of an image composed of back-
ground tissue and a tumor are displayed. Both profiles demonstrated a
contrast of 1 or a contrast-to-background ratio of 11, but owing to large
differences in noise characteristics, the location of the tumor is much
easier to see in the red profile with a contrast-to-noise ratio (CNR) of
16.0 than in the blue profile with a CNR of 1.6. A CNR profile from
the dual-reporter image displayed in Fig. 5(f) is also presented as a
solid black line for comparison.
Fig. 3 Fluorescence and dual-reporter images at 1 h after dual-reporter
injection. Columns 1 to 4 display a typical preimaging white light pic-
ture and corresponding untargeted fluorescence uptake (IRdye 700DX),
targeted fluorescence uptake (EGF-IRdye 800CW), and dual-reporter
images of each tumor line (row 1 ¼ A431, row 2 ¼ U251, row
3 ¼ 9L-GFP, and row 4 ¼ blocked U251), respectively. The location
of the tumor is highlighted for each case on the white-light image by
the dashed yellow line.
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at all time points after injection (even at 1 min) for the U251 and
A431 tumor lines, and by 20 min after reporter injection for the
9L-GFP tumor line (P < 0.001). The dual-reporter image CNR
of the blocked U251 tumors never reached a level of signifi-
cance over the background. Moreover, by 20 min, the average
dual-reporter image value in the tumor [Eq. (6)] measured in
each tumor group was significantly different from all other
tumor groups, and the difference correlated with the expected
differences in EGFR expression between the groups. More spe-
cifically, at 20 min, the average tumor dual-reporter CNR in the
blocked U251 line, expected to express the least amount of
EGFR, was 67 59; in the 9L-GFP line, expected to express
a little amount of EGFR, was 116 49; in the U251 line,
expected to express a moderate level of EGFR, was
578 59; and in the A431 line, expected to express the most
EGFR of the tumor lines, was 922 172. To investigate this
relationship further, correlation plots were created relating the
dual-reporter tumor value at 2 min [Fig. 4(c)] and 1 h [Fig. 4(d)]
to the in vivo binding potential, a quantitative marker of receptor
expression that has been validated against ex vivo and in vitro
measures.21 This approach takes as input the full temporal
uptake curve of the targeted and untargeted reporters in the
first hour after injection and employs a simplified reference tis-
sue model22 to measure binding potential using the uptake of
the untargeted reporter as a “reference tissue.”A statistically sig-
nificant correlation was observed between the two measures at
20 min and 1 h, with slopes of 0.61 0.12 (P < 0.05, r ¼ 0.89)
and 0.68 0.05 (P < 0.01, r ¼ 0.94), respectively.
Although the dual-reporter approach demonstrated obvious
improvements over targeted fluorescence uptake alone for the
localization of EGFR-expressing cancerous tissue, fluorescence
uptake is generally measured at much longer time points after
injection because of the known lack of sensitivity at early time
points.31 For comparison, targeted and untargeted fluorescence
uptakes were also measured in a separate set of U251 and
blocked U251 mice at a single time point 24 h after reporter
injection. Figure 5(a) shows a box-plot of the targeted fluores-
cence uptake at both 24 h and 1 h for the U251 and blocked
U251 groups. As demonstrated by the plot, the only group
that presented an average tumor CNR that was significantly
Fig. 4 Targeted fluorescence uptake versus dual-reporter imaging within 1 h of reporter injection. The mean standard error targeted fluorescence
uptake tumor contrast-to-noise ratio (CNR) within 1 h of reporter injection is presented in (a) for each tumor group (A431 ¼ red; U251 ¼ blue;
9L-GFP ¼ black; blocked U251 ¼ dark yellow). The mean standard error tumor CNR determined by the dual-reporter approach for the same
tumor groups as in (a) is presented in (b). The correlation between the average dual-reporter image value of the tumor in each mouse at 20 min
and 1 h after reporter injection and the corresponding binding potential (an in vivo marker of receptor expression) are presented in (c) and (d), respec-
tively. Data points from each tumor line are color-coded to match the data in (a) and (b). The slope of the 20-min correlation was 0.61 0.12 (r ¼ 0.89,
P < 0.05), and the 1-h correlation was 0.68 0.05 (r ¼ 0.94, P < 0.01).
Journal of Biomedical Optics 066001-5 June 2012 • Vol. 17(6)
Tichauer et al.: Improved tumor contrast achieved by single time point dual-reporter fluorescence imaging
different from zero (p < 0.001)—i.e., measurable from the back-
ground—was the fluorescence at 24 h in the unblocked U251
group, with a CNR of 217 78. For comparison, Fig. 5(b)
displays dual-reporter tumor CNR data for the same groups
as in Fig. 5(a). For this measure, the tumor CNRs of both
the 1- and 24-h dual-reporter values in the unblocked U251
mice were significantly different from zero (P < 0.001), whereas
the dual-reporter value in the blocked groups was not. The aver-
age dual-reporter tumor CNR at 1 h was 503 58, and at 24 h
was 631 175 (there was no statistically significant difference
between these). Of note, the dual-reporter tumor CNR was sig-
nificantly higher than the targeted fluorescence CNR at 24 h
(P < 0.01). Examples of the targeted fluorescence uptake
image and the dual-reporter image from a single U251
Fig. 5 Tumor contrast-to-noise ratio (CNR) comparison is shown between targeted fluorescence uptake and dual-reporter images. A box-plot of the
tumor CNR determined from targeted fluorescence uptake images at 1 and 24 h after reporter injection in mice with blocked (FL B) and unblocked (FL)
U251 tumors are presented in (a). Each data point represents an individual average tumor CNR from one mouse. Blue data points represent measure-
ments taken in unblocked U251 tumors and red data points represent measurements taken in blocked U251 tumors. A similar box plot is presented in
(b), with the tumor CNR determined from the dual-reporter (DR) images at 1 and 24 h after reporter injection. Examples of the targeted fluorescence
uptake images at 1 and 24 h are presented in (c) and (e), respectively, and examples of the dual-reporter images at 1 and 24 h are presented in (d) and (f).
The maximum value in each image was chosen as the maximum threshold of the color scale, and the lower threshold was chosen independently in
each image by a receiver operating characteristic analysis to optimize the tumor CNR in each case.
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mouse at 1 h after reporter injection are presented in Fig. 5(c)
and 5(d), respectively, and examples from a single U251 mouse
at 24 h after reporter injection are presented in Fig. 5(e) and 5(f).
The maximum value in each image was chosen as the maximum
threshold of the color scale, and the lower threshold was chosen
independently in each image by ROC analysis to optimize the
tumor CNR in each case and observe the ultimate potential of
each approach.
A more in-depth analysis of the benefits of dual-reporter ima-
ging over targeted fluorescence alone is presented in Fig. 6. In
Fig. 6(a), typical ROC curves for the different approaches of
localizing cancerous tissue (targeted fluorescence uptake or
dual-reporter imaging at 1 or 24 h after reporter injection)
are presented for U251 mice. By applying the area-under-the-
curve analysis to each cancer localization approach for each
mouse, the average accuracy of the targeted fluorescence uptake
approach was estimated to be 60% 13% and 90% 5% at 1
and 24 h after reporter injection, respectively. The average accu-
racy of the dual-reporter approach was 96% 2% and 98%
1% at 1 and 24 h after reporter injection. The improved accuracy
of the dual-reporter approach at 1 and 24 h postinjection over the
targeted fluorescence uptake approach at 24 h was statistically
significant (P < 0.001 for the 24-h dual-reporter approach com-
pared to 24-h fluorescence uptake and P < 0.05 for the 1-h dual-
reporter approach compared to the 24-h fluorescence uptake).
Fluorescence uptake in the kidney of targeted and untargeted
reporters was visible in 3 of the 6 24-h U251 mice [Fig. 7(a) and
7(b)]. As the kidney is the major filtering organ of these repor-
ters, signal from the kidney can be a significant source of non-
receptor-mediated fluorescence uptake.32 To avoid potential
bias, the kidney was not included in the ROC analyses presented
in Fig. 6; however, it is a strength of the dual-reporter approach
that the kidney, although dominant in the targeted and untar-
geted fluorescence uptake images, was not visible in the
dual-reporter images [Fig. 7(c)]. Image thresholds for Fig. 7
were selected based on optimal thresholds from ROC analyses
of each image, independently.
4 Discussion
Use of fluorescence-guided surgery (FGS) in oncology has been
limited, yet is growing in applications. Typically, receptor-
mediated guidance would involve three steps. The first step
would be systemic administration of the fluorescent molecule
that is targeted to a cancer-specific receptor (e.g., EGFR).
The second step would be to wait for the fluorescence to be car-
ried by the blood throughout the body, and then, importantly, to
wait for the washout of any nonspecific uptake of the targeted
fluorescence to ensure that the tumor-to-background CNR is
maximal for tumor delineation. The third step would then be
the surgery, removing any suspicious tissue that is highlighted
Fig. 6 Receiver operating characteristic (ROC) analysis was used, where typical ROC curves for the dual-reporter approach at 1 h after reporter injec-
tion (blue line) and 24 h after injection (red line), and for the targeted fluorescence uptake approach at 1 h after injection (dark yellow line) and 24 h
after injection (dashed black line) are presented in (a) for a 1-h U251 mouse and a 24-h U251 mouse. The areas-under-the-curve (approximate accura-
cies) of each ROC curve for all U251 mice at 1 and 24 h using the targeted fluorescence uptake approach (FL) and the dual-reporter approach (DR) are
displayed in boxplots in (b). The color-coding matches that in (a). Each data point corresponds to an independent accuracy measurement for a single
mouse using a single approach.
Fig. 7 Qualitative specificity of targeted fluorescence uptake and dual-
reporter approaches for localizing cancerous tissue is shown. Examples
of an untargeted fluorescence uptake image (a) and a corresponding
targeted fluorescence uptake image (b) and dual-reporter image
(c) at 24 h in a U251 mouse are presented. The solid white arrow points
to the location of the tumor, and the dashed white arrow points to the
location of a kidney. Images are thresholded to optimize tumor locali-
zation based on a receiver operating characteristic analysis.
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by abnormally high fluorescence uptake. The problem with this
approach is that the uptake of a targeted reporter in a specific
region of interest is not just governed by that region’s targeted
receptor expression; other physiological factors play roles as
well, such as blood flow, vessel permeability, cellular interna-
lization, interstitial pressure, and other nonreceptor-mediated
mechanisms of reporter uptake and retention.33 Therefore a
cancerous lesion with a low blood supply or a high interstitial
pressure may exhibit low fluorescence uptake despite overex-
pressing the targeted receptor or an organ that acts to filter
agents from the bloodstream (kidney, liver, spleen) may have
substantial fluorescence uptake despite expressing no specific
receptor. At this early time in the development of fluorescence
guidance, it is still not clear if bulk uptake of reporter might have
advantages over binding assay reporters; however, it is clearly
true that most conventional approaches to this problem have not
been able to attribute their signal uniquely to binding alone. This
study presents a dual-reporter imaging approach that was
designed to mitigate the nonreceptor-mediated effects of tar-
geted reporter uptake by accounting for them with the measure-
ment of a simultaneously injected untargeted fluorescence
reporter. Fluorescence was imaged on an Odyssey system,
which is a flat-panel scanner, incapable of use during surgery.
This system was employed to study the potential for dual-
reporter imaging to be done, since it is optimized to eliminate
cross-talk between concentrations of the two LI-COR fluores-
cent reporters used. Further studies are ongoing to test out
the approaches of this study using a hyperspectral fluorescence
surgical microscope.
In Sec. 2, an expression was derived, building upon earlier
work,20 relating the uptake of a targeted imaging reporter and an
untargeted reporter in a region of interest with the binding poten-
tial in that region (a parameter directly proportional to the
targeted receptor density27). To investigate the utility of this
approach, the uptakes of the two fluorescent reporters (one tar-
geted to EGFR and one untargeted) were tracked over the first
1 h after injection in four tumor groups (A431, U251, 9L-GFP,
and U251 blocked) and at 24 h in U251 and U251 blocked
groups. The results were used to compare the dual-reporter
approach against conventional targeted fluorescence uptake
imaging with regard to tumor discrimination.
There were two salient findings of the current study. The first
was that the dual-reporter approach for tumor discrimination,
when applied at 1 or 24 h after reporter injection, was superior
at discriminating the tumor compared to the more conventional
approach of measuring targeted fluorescence uptake alone at 1
and 24 h postinjection (Figs. 5 and 6), in terms of both tumor-to-
background CNR and area under the ROC curve. This is a major
finding, since surgical guidance by targeted fluorescence alone
has been highly touted to improve the success rate of tumor
resections, and this study suggests that employing a dual-
reporter approach can improve the ability to discriminate
between tumor and healthy tissue even further. Moreover,
because the dual-reporter approach is so successful at relatively
early times after reporter injection (1 h), it could require lower
dosages of imaging reporters, which may improve the potential
for new reporters to gain clinical approval.34 Additionally, the
signal attained at these early points is more likely to be driven
by targeted receptor availability as opposed to longer-term
effects such as cellular internalization. If the goal is simply
to discriminate between tumor and healthy tissue, though, cel-
lular internalization may actually improve the contrast, as seen
by the fact that the 24-h dual-reporter images were roughly
equivalent in performance to the 1-h dual-reporter images
despite having poorer signal-to-noise characteristics because
of prolonged fluorescence washout (the SNR in the fluorescence
images was approximately 3 times higher at 1 h than at 24 h).
However, if the goal is also to estimate the level of targeted
receptor expression, the influence of cellular internalization
should be avoided, since this will cause the receptor expression
to be overestimated (the average dual-reporter value in U251
tumors was 3.5 0.3 at 1 h after fluorescence injection and
10.6 1.2 at 24 h). An interesting caveat to the dual-reporter
images is that they are not as affected by signal contamination
in organs of filtration. The reporters used in this study are less
than 5.5 nm in diameter and are therefore preferentially filtered
by the kidney.35,36 Significant untargeted and targeted fluores-
cence signal from the kidney was evident in three of the
24-h mice; however, since the uptake of the two reporters
was relatively equivalent, any signal from the kidney was nor-
malized out in the dual-reporter images (Fig. 7). The upshot of
this is that the dual-reporter approach could make it possible to
localize tumors that are proximal to organs of filtration, a feat
that would be very difficult using targeted fluorescence
uptake alone.
The second salient finding of this study was that by 20 min
after reporter injection, the dual-reporter approach demonstrated
a statistically significant correlation with a more robust in vivo
measure of the binding potential that employed fitting the full
time courses of fluorescence uptake of both reporters [Fig. 4(c)].
This robust binding potential measure makes fewer physiologic
assumptions than the dual-reporter approach and has been vali-
dated in a previous study against ex vivo and in vitromeasures of
receptor density.21 Although it represented a strong correlation,
the slope of the regression was significantly different from 1
(0.68 0.05), probably because there is approximately 10
times greater autofluorescence in the 700-nm (untargeted) fluor-
escence channel than in the 800-nm (targeted) fluorescence
channel. This would lead to an overestimation of the untargeted
fluorescence uptake, and from Eq. (6), it can be seen that this
overestimation will lead to an underestimation in the numerator
and an overestimation in the denominator, compounding to
cause a magnified underestimation in the single time point—
derived binding potential. It is possible to account for the
increased autofluorescence in the 700-nm channel by collecting
a pre-reporter injection scan, which can be subtracted from sub-
sequent scans. However, in the field of fluorescence-guided sur-
gery where the imaging field could be constantly changing, it
would be better to develop an approach that would be insensitive
to motion. Indeed, the strength of the correlation between the
dual-reporter value and binding potential presented in Fig. 3(c),
which was significant from 20 min on, demonstrates that this
approach has the potential to provide a real-time, motion-insen-
sitive measure of receptor density and therefore can discriminate
between tissues based on receptor density, and receptor den-
sity alone.
Activatable fluorescence reporters that do not fluoresce
unless bound to a specific receptor of interest constitute another
approach to amplify receptor density—derived contrast in
FGS.6,16 Because these reporters provide contrast only where
activator is present, many of the factors that involve nonrecep-
tor-mediated reporter uptake and could confound conventional
FGS are avoided; however, the contrast is still founded on
reporter binding as opposed to receptor density as with the
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dual-reporter approach. This means that the amount of activated
fluorescence is still influenced, perhaps strongly, by the hemo-
dynamics, vascular permeability, and interstitial pressure of the
region of interest, all of which can vary substantially both
between and within tumors.37 The proposed dual-reporter
approach avoids these factors by essentially referencing the
uptake of the targeted reporter to the untargeted reporter. There-
fore, the sensitivity of this approach is predominantly governed
by the dynamic range of the imaging modality used to detect the
fluorescence. In other words, if the assumptions of the dual-
reporter theory hold, the approach is only susceptible to fluor-
escence detection saturation or areas with a limited SNR, which
could occur in areas of necrosis.
Reiterating the Methods, the dual-reporter expression relat-
ing the uptake of the targeted and untargeted reporters with the
level of receptor expression [Eq. (6)] relies on the following
assumptions: that the plasma and free-space components of
the respective reporter concentrations in tissue are roughly
equivalent, that the bound and unbound states of the targeted
reporter are in an instantaneous equilibrium (i.e., the adiabatic
approximation holds22), that the tissue concentration of the
untargeted reporter is predominantly composed of reporter in
the extravascular space (i.e., the plasma component is approxi-
mately negligible or equivalent in all cases), and that the targeted
tracer concentration is considerably less than the receptor
concentration to avoid receptor saturation effects. The strength
of the results in the current study suggests that each of these
assumptions is adequate; however, further investigation is neces-
sary to fully characterize the utility of the presented FGS
technique. In a previous study, the plasma curves of IRDye
800CW-EGF and IRDye 700DX (the targeted and untargeted
agents used in this study) were found to be very similar in
immune-compromised mice, being approximated by exponen-
tial decay functions with half-lives of approximately 8 min,26
and studies are ongoing to investigate the reliability of the
other model assumptions under different physiological condi-
tions (nonspecific binding and cellular internalization) using
a full kinetic forward model. Furthermore, we are investigating
the potential of employing an enantiomer of the targeted reporter
as an untargeted reporter to minimize any differences between
the two. For example, for EGFR targeting it would be possible
to use an anti-EGFR Affibody® imaging agent for the targeted
reporter and a negative control Affibody imaging agent for the
untargeted reporter.38,39 With respect to receptor saturation, it
may be possible to include second-order kinetics in the
model to account for this;40 however, keeping injected fluores-
cence at tracer levels (i.e., far below receptor saturation) will
likely be important for clinical translation. In a previous
study, we demonstrated that a 1-nmol dose of IRDye
800CW-EGF in mice would be far below saturation levels
for a tumor of similar EFGR expression.26 Another factor
that can also affect the efficacy of the dual-reporter approach
is the influence of specific uptake from other organs. More spe-
cifically, the technique requires that the tumor of interest
expresses significantly more of the targeted receptor than the
surrounding tissue. This could be a problem for EGFR targeting,
for example, if the tumor is proximal to an organ like the pan-
creas, which is known to express a significant amount of
EGFR.26,41
In conclusion, the current study introduces a novel fluores-
cence-guided surgery technique that utilizes a secondary, untar-
geted imaging reporter to account for nonreceptor-mediated
uptake of the targeted fluorescence. This dual-reporter approach
was demonstrated to provide instantaneous maps that could be
used to discriminate between cancerous and healthy tissue with
significantly better contrast-to-noise and ROC analysis charac-
teristics than targeted fluorescence uptake alone. Furthermore,
by 20 min after injection of the fluorescent reporters, the average
dual-reporter image values in a range of tumor types demon-
strated a significant correlation with tumor binding potential
(a measure of receptor expression). Therefore, not only does
the dual-reporter approach outperform conventional fluores-
cence intensity imaging for tumor/healthy tissue discrimination,
but it also provides an estimate of tumor receptor status, which
could be used to inform the choice or progress of biological
therapies that target the same receptors.10,42
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